SCYX — SCYNEXIS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1178253 ·
Last close
$2.85
Market Cap
$28.37M
52W High
$9.12
52W Low
$2.70
ADV30
82,124
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -9,761,000 | -8,458,000 | 67,951,000 | 8,228,000 | 8,904,000 |
| Jun 2026 | 235,000 | — | -7,775,000 | 7,397,000 | 74,970,000 | 10,487,000 | 8,040,000 |
| Mar 2026 | 0 | — | -16,939,000 | -21,299,000 | 77,626,000 | 36,671,000 | 36,319,000 |
| Dec 2025 | 18,646,000 | — | 10,521,000 | 12,258,000 | 59,027,000 | 21,259,000 | 9,651,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-13,309,000
Investing CF
$-24,690,000
Financing CF
$37,411,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-5.20
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-399,046,000
Inventory
—
Receivables
$0
ST Investments
$43,596,000
EBIT TTM
$-10,235,000
Pretax Income TTM
$-10,235,000
Interest Exp TTM
$0
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$19,216,000
EBITDA
—
Free Cash Flow
$-7,323,375
Enterprise Value
$-19,304,290
Total Cash
$54,083,000
Total Debt
$1,945,000
Shares Out
9,953,155
Trailing EPS
$-0.23
Book Value
$9.07
ROE
-18.4%
ROA
-20.8%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 20,601,000 | -16,074,000 | -8,609,000 | 59,027,000 | 9,651,000 | 49,376,000 | -5,283,000 |
| Dec 2024 | 3,746,000 | -37,117,000 | -21,288,000 | 90,643,000 | 35,566,000 | 55,077,000 | -24,009,000 |
| Dec 2023 | 140,141,000 | 72,669,000 | 67,041,000 | 128,412,000 | 55,450,000 | 72,962,000 | 60,159,000 |
| Dec 2022 | 5,091,000 | -85,757,000 | -62,809,000 | 87,810,000 | 84,577,000 | 3,233,000 | -79,883,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$19,215,000
NetIncome TTM
$-10,235,000
OpCashFlow TTM
—
Assets (Latest)
$74,970,000
Forward EPS
$-2.31
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $2.82 · call volume: 101 · put volume: 5
Expected Move to 2026-12-18:
±$0.96
(34.04%) —
implied range
$1.86 –
$3.78
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PYRGF | PyroGenesis Canada Inc. | $28.34M | $0.13 | — |
| PMN | ProMIS Neurosciences Inc. | $28.88M | $3.21 | — |
| RDPTF | Radiopharm Theranostics Ltd | $28.89M | $0.01 | — |
| AYTU | AYTU BIOPHARMA, INC | $28.91M | $2.66 | — |
| BHST | BIOHARVEST SCIENCES INC. | $27.65M | $1.22 | — |
News headlines (Yahoo Finance, 1h cache)
Scynexis: Q3 Earnings Snapshot
2026-11-05 13:27 · Yahoo
SCYNEXIS Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-05 13:20 · Yahoo
SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference
2026-10-29 12:00 · Yahoo
SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases
2026-10-22 12:00 · Yahoo
SCYNEXIS to Feature SCY-247 in a Pipeline Presentation at IDWeek
2026-10-21 20:05 · Yahoo
SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
2026-10-06 11:30 · Yahoo
Scynexis stock surges on $214M BARDA contract for SCY-247
2026-09-28 13:58 · Yahoo
Scynexis Shares Rise 13.9% After BARDA Awards SCY-247 Development Contract
2026-09-28 12:10 · Yahoo
SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247
2026-09-28 11:30 · Yahoo
SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors
2026-09-22 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.